logo
Share SHARE
FONT-SIZE Plus   Neg

ISTA Pharma Presents Results From One Of Two Phase 3 Studies Of PROLENSA

ISTA Pharmaceuticals, Inc. (ISTA) presented results from one of two Phase 3 studies of PROLENSA (bromfenac ophthalmic solution), the company's once-daily topical nonsteroidal anti-inflammatory product candidate for the treatment of ocular inflammation and pain following cataract surgery.

According to the company, the findings showed PROLENSA was statistically greater than placebo in clearing subjects' ocular inflammation by day 15 and eliminating ocular pain one day post-surgery, the study's primary and secondary endpoints, respectively.

ISTA Pharma noted that it plans to file a New Drug Application with the U.S. Food and Drug Administration, or FDA, for PROLENSA in the first half of 2012.

Also, additional data from the poster presentation, titled "Phase III Clinical Trial of Low Concentration Bromfenac Ophthalmic Solution Dosed Once Daily for Postoperative Ocular Inflammation and Pain", showed there were no serious drug-related ocular or systemic adverse events, and PROLENSA's safety profile was consistent with the company's currently marketed once-daily topical nonsteroidal anti-inflammatory compound, BROMDAY (bromfenac ophthalmic solution) 0.09%.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Nintendo has launched a new handheld gaming system Galaxy 3DS XL. The new game will combine portable gaming along with 3D technology. Priced at $199.99, it will be available on stores from this week. Mitsubishi Motors Corp. has suspended sales of eight car models in Japan after the country's Transport Ministry said the automaker overstated the fuel-economy figures for those models. Japan's Transport Ministry has ordered Mitsubishi to stop domestic sales of the eight vehicle models and submit correct fuel-economy readings for these vehicles The European Union's executive arm has ordered the Irish government to recover up to 13 billion euros, or $14.5 billion, in taxes from Apple Inc. The European Commission said it has concluded that Ireland granted the U.S. tech giant undue tax benefits of up to 13 billion euros, which is illegal under EU state aid rules. Shares of Apple are down 1 percent in pre-market activity.
comments powered by Disqus
Follow RTT